GSK Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by GSK Plc, dated May 13, 2024, reports on the company's employee share schemes for the six-month period from November 1, 2023, to April 30, 2024. The document serves as a Block Listing Six Monthly Return required under UK Listing Rules.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. It exclusively details the movement of unallotted securities under three specific share schemes:
- GlaxoSmithKline plc 2017 Deferred Annual Bonus Plan: 155,789 securities issued; ending balance of 115,518 unallotted securities.
- GlaxoSmithKline plc Share Save Plan 2012: 2,000,000 securities added to the scheme; 1,833,574 securities issued; ending balance of 673,024 unallotted securities.
- GlaxoSmithKline plc Share Save Plan 2022: 3,852 securities issued; ending balance of 995,257 unallotted securities.
Material Changes
The primary material change reported is the increase of 2,000,000 securities in the Share Save Plan 2012 block scheme during the reporting period. No increases were applied for in the other two schemes.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items. It is a regulatory disclosure of share scheme activity only.
Key Facts for Investor Verification
- Verify the total number of shares issued under the Share Save Plan 2012 (1,833,574) against the company's broader capital allocation strategy.
- Confirm the remaining unallotted balance across all three schemes totals 1,783,799 shares.
- Note that this filing does not reflect the company's operational or financial performance for the period.